Saltar al contenido
Merck
  • Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review.

Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review.

Canadian oncology nursing journal = Revue canadienne de nursing oncologique (2014-01-17)
Teresa Ruston, Kathleen Hunter, Greta Cummings, Adriana Lazarescu
RESUMEN

Opioid-induced constipation (OIC) is a side effect of opioid therapy that can affect quality of life, adherence to treatment, and morbidity and possibly mortality. To investigate whether docusate sodium, sennosides, and lactulose have equal efficacy and side effect profiles compared to PEG in the management of OIC in adults. A systematic review was undertaken. Randomized controlled trials of adults taking opioids for cancer or non-cancer pain were considered if they met inclusion criteria. Statistical pooling was not possible as no studies met inclusion criteria. Large, well-powered, randomized controlled trials are feasible. Standard definitions of OIC would assist with the execution of these studies and contribute to their internal and external validity. Further research is strongly encouraged.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dioctyl sulfosuccinate sodium salt, ≥97%
Sigma-Aldrich
Lactulose, ≥98.0% (HPLC)
Sigma-Aldrich
Docusate sodium salt, BioXtra, ≥99%
Sigma-Aldrich
Lactulose, ≥95% (HPLC)
Sigma-Aldrich
Docusate sodium salt, BioUltra, ≥99.0% (TLC)
Sigma-Aldrich
Docusate sodium, meets USP testing specifications
Sigma-Aldrich
Docusate sodium salt, purum, ≥96.0% (TLC)
USP
Lactulose, United States Pharmacopeia (USP) Reference Standard
Docusate sodium, European Pharmacopoeia (EP) Reference Standard
Lactulose for peak identification, European Pharmacopoeia (EP) Reference Standard
Lactulose, European Pharmacopoeia (EP) Reference Standard